Heartflow (NASDAQ:HTFL) CFO Vikram Verghese Sells 6,640 Shares

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 6,640 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $50.03, for a total value of $332,199.20. Following the completion of the sale, the chief financial officer directly owned 214,503 shares in the company, valued at $10,731,585.09. This trade represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total value of $1,368,462.60.
• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The stock was sold at an average price of $50.60, for a total transaction of $297,325.60.

Heartflow Trading Down 2.5%

HTFL opened at $45.49 on Friday. The company has a market cap of $3.96 billion and a P/E ratio of -24.86. The company’s 50 day moving average is $35.08 and its 200-day moving average is $30.65. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $51.78.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, equities analysts forecast that Heartflow, Inc. will post -0.75 EPS for the current year.

Institutional Investors Weigh In On Heartflow

A number of institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Heartflow in the fourth quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new stake in Heartflow during the 4th quarter valued at approximately $45,000. Integrated Wealth Concepts LLC bought a new position in Heartflow during the 2nd quarter worth approximately $53,000. Essential Partners LLC bought a new position in Heartflow during the 1st quarter worth approximately $57,000. Finally, Legal & General Group Plc acquired a new stake in shares of Heartflow during the third quarter worth $59,000.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. increased their price target on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Canaccord Genuity Group boosted their price objective on Heartflow from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 target price (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. Wells Fargo & Company increased their target price on Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Finally, Benchmark restated a “buy” rating on shares of Heartflow in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and an average price target of $44.88.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.